{"protocolSection": {"identificationModule": {"nctId": "NCT06346392", "orgStudyIdInfo": {"id": "D9802C00001"}, "secondaryIdInfos": [{"id": "2023-508276-11-00", "type": "REGISTRY", "domain": "CTIS (EU)"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2", "officialTitle": "A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.", "detailedDescription": "This is a Phase III, multi-center, open-label, sponsor-blinded, randomized, global study to assess the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as the 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2, and the clinical performance of the investigational IVD. As part of this combined approach, the efficacy analyses from this study will also provide the basis to evaluate the clinical performance of Ventana CLDN18.2 assay as an IVD device for the identification of patients with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2 who may benefit from AZD0901."}, "conditionsModule": {"conditions": ["Gastric Cancer", "Gastroesophageal Junction Cancer"], "keywords": ["Gastric cancer", "Gastroesophageal junction cancer", "Phase III", "Claudin 18.2", "AZD0901"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Participants will be randomized in a 1:1:1 ratio to one of the following intervention arms until the dose selection decision is made:\n\nArm 1: AZD0901 arm 1 IV, Q3W Arm 2: AZD0901 arm 2 IV, Q3W Arm 3: Participants in the Investigator's choice arm, including regionally accepted chemotherapies or targeted therapies 2L: Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W 2L: Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only) 2L: Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only) 3L+: Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W 3L+: TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China) 3L+: Apatinib 500-850 mg, orally once daily, Q4W (China only)", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "maskingDescription": "This is an open-label study; however, it will be conducted 'sponsor-blind' and the specific treatment to be taken by a participant will be assigned using an IRT/RTSM. To maintain the integrity of the study, sponsor access to treatment records will be restricted, and, in particular, under no circumstances will the sponsor undertake any efficacy analysis by treatment arm during the study. A Study Integrity Plan will be generated in which nominated individuals who will be granted access to any treatment-revealing data will be pre-specified, with their reason for requiring access detailed.", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 589, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "AZD0901 arm 1", "type": "EXPERIMENTAL", "description": "Participants in the AZD0901 arm 1 will receive AZD0901 dose level 1 intravenous infusion treatment.", "interventionNames": ["Drug: AZD0901"]}, {"label": "AZD0901 Arm 2", "type": "EXPERIMENTAL", "description": "Participants in the AZD0901 arm 2 will receive AZD0901 dose level 2 intravenous infusion treatment.", "interventionNames": ["Drug: AZD0901"]}, {"label": "Investigator's choice arm", "type": "ACTIVE_COMPARATOR", "description": "Participants in the Investigator's choice arm will receive a regimen of Investigator's choice, including regionally accepted chemotherapies or targeted therapies.", "interventionNames": ["Drug: Ramucirumab+ paclitaxel", "Drug: Paclitaxel", "Drug: Docetaxel", "Drug: Irinotecan", "Drug: TAS-102", "Drug: Apatinib"]}], "interventions": [{"type": "DRUG", "name": "AZD0901", "description": "Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV", "armGroupLabels": ["AZD0901 arm 1"]}, {"type": "DRUG", "name": "AZD0901", "description": "Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV", "armGroupLabels": ["AZD0901 Arm 2"]}, {"type": "DRUG", "name": "Ramucirumab+ paclitaxel", "description": "Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W", "armGroupLabels": ["Investigator's choice arm"]}, {"type": "DRUG", "name": "Paclitaxel", "description": "Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)", "armGroupLabels": ["Investigator's choice arm"]}, {"type": "DRUG", "name": "Docetaxel", "description": "Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)", "armGroupLabels": ["Investigator's choice arm"]}, {"type": "DRUG", "name": "Irinotecan", "description": "Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W", "armGroupLabels": ["Investigator's choice arm"]}, {"type": "DRUG", "name": "TAS-102", "description": "TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)", "armGroupLabels": ["Investigator's choice arm"]}, {"type": "DRUG", "name": "Apatinib", "description": "Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)", "armGroupLabels": ["Investigator's choice arm"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Capable of giving signed informed consent prior to any study procedure.\n2. Participant must be at least 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.\n3. Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of gastric, GEJ, or distal esophagus (distal third of the esophagus) and the following requirement:\n\n   (a) Participants with positive CLDN18.2 expression from archival tumor collected within past 24 months or from a fresh biopsy.\n4. Disease progression on or after at least one prior line of treatment (LoT) for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease.\n5. Must have at least one measurable or evaluable lesion assessed by the Investigator based on RECIST 1.1.\n6. ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.\n7. Predicted life expectancy of \u2265 12 weeks.\n8. Adequate organ and bone marrow function\n9. Body weight of \u2265 35 kg.\n10. Sex and Contraceptive Requirements\n\nExclusion Criteria:\n\n1. Participants with known HER2 positive status as defined as IHC 3+ or IHC 2+/ISH + (Cases with HER2: CEP17 ratio \u2265 2 or an average HER2 copy number \u2265 6.0 signals/cell are considered positive by ISH). Participants must undergo local (or have had) HER2 testing by IHC/ISH, and the most recent result of HER2 status will be used to determine the eligibility.\n2. Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers.\n3. CNS metastases or CNS pathology including: epilepsy, seizures, aphasia, or stroke within 3 months prior to consent, severe brain injury, dementia, Parkinson's disease, neurodegenerative diseases, cerebellar disease, severe uncontrolled mental illness, psychosis, CNS involvement of autoimmune diseases.\n4. Participant has known clinically significant corneal disease (eg, active keratitis or corneal ulcerations).\n5. Persistent toxicities (CTCAE Grade \u2265 2) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss).\n6. Prior exposure to any ADC with MMAE payload or any CLDN18.2 targeting treatment other than naked monoclonal antibody (eg, CLDN18.2 targeting CAR-T cell therapy, multi-specific antibody including targeting CLDN18.2, etc).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "130 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "AstraZeneca Clinical Study Information Center", "role": "CONTACT", "phone": "1-877-240-9479", "email": "information.center@astrazeneca.com"}]}}, "hasResults": false}